Platelet-rich plasma (PRP) impairs the craniofacial bone repair associated with its elevated TGF-β levels and modulates the co-expression between collagen III and α-smooth muscle actin

Journal of Orthopaedic Research

Volumn 29, Issue 3, 2011, Pages 457-463

  Giovanini, Allan Fernando ^a   Gonzaga, Carla Castiglia ^a   Zielak, João Cesar ^a   Deliberador, Tatiana Miranda ^a   Kuczera, Juliane ^a   Göringher, Isabella ^a   De Oliveira Filho, Marco Antonio ^b   Baratto Filho, Flares ^a   Urban, Cícero Andrade ^a  

^a POSITIVO UNIVERSITY   (Brazil)

^b University Evangelic Hospital   (Brazil)

Author keywords

bone regeneration; fibrosis; platelet rich plasma; smooth muscle actin; type III collagen

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; BIOMATERIAL; COLLAGEN TYPE 3; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; AUTOGRAFT; BONE DEFECT; BONE MATRIX; BONE REMODELING; CALVARIA; CONTROLLED STUDY; CRANIOFACIAL SURGERY; FEMALE; IMMUNOHISTOCHEMISTRY; MORPHOMETRICS; NONHUMAN; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEIN EXPRESSION; RABBIT; THROMBOCYTE RICH PLASMA;

ACTINS; ANIMALS; BONE REGENERATION; BONE TRANSPLANTATION; COLLAGEN TYPE III; FEMALE; FIBROBLASTS; IMMUNOHISTOCHEMISTRY; PLATELET-RICH PLASMA; RABBITS; SKULL; TRANSFORMING GROWTH FACTOR BETA; TRANSPLANTATION, AUTOLOGOUS;

EID: 79251535040     PISSN: 07360266     EISSN: 1554527X     Source Type: Journal    
DOI: 10.1002/jor.21263     Document Type: Article

References (43)

1. Marx RE,. 2004. Platelet-rich plasma: evidence to support its use. J Oral Maxillofac Surg 62: 489-496.
2. Freymiller EG, Aghaloo TL,. 2004. Platelet-rich plasma: ready or not? J Oral Maxillofac Surg 62: 484-488.
3. Nikolidakis D, Jansen JA,. 2008. The biology of platelet-rich plasma and its application in oral surgery: literature review. Tissue Eng Part B Rev 14: 249-258.
4. Klongnoi B, Rupprecht S, Kessler P, et al. 2006. Lack of beneficial effects of platelet-rich plasma on sinus augmentation using a fluorohydroxyapatite or autogenous bone: an explorative study. J Clin Periodontol 33: 500-509.
5. Blakytny R, Ludlow A, Martin GE, et al. 2004. Latent TGF-β1 activation by platelets. J Cell Physiol 199: 67-76.
6. Massague J, Gomis RR,. 2006. The logic of TGF β signaling. FEBS Lett 580: 2811-2820.
7. Wynn TA,. 2007. Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases. J Clin Invest 117: 524-529.
8. Wells RG,. 2000. Fibrogenesis. V. TGF-β signaling pathways. Am J Physiol Gastrointest Liver Physiol 279: G845-G850.
9. Pohlers D, Brenmoehl J, Loffler I, et al. 2009. TGF-β and fibrosis in different organsa-molecular pathway imprints. Biochim Biophys Acta 1792: 746-756.
10. Shehata M, Schwarzmeier JD, Hilgarth M, et al. 2004. TGF-β1 induces bone marrow reticulin fibrosis in hairy cell leukemia. J Clin Invest 113: 676-685.
11. Folkman J, Moscona A,. 1978. Role of cell shape in growth control. Nature 273: 345-349.
12. Wells RG, Discher DE,. 2008. Matrix elasticity, cytoskeletal tension, and TGF-β: the insoluble and soluble meet. Sci Signal 1: pe13.
13. Artaza JN, Singh R, Ferrini MG, et al. 2008. Myostatin promotes a fibrotic phenotypic switch in multipotent C3H 10T1/2 cells without affecting their differentiation into myofibroblasts. J Endocrinol 196: 235-249.
14. Tang WW, Van GY, Qi M,. 1997. Myofibroblast and alpha 1 (III) collagen expression in experimental tubulointerstitial nephritis. Kidney Int 51: 926-931.
15. Hinz B, Phan SH, Thannickal VJ, et al. 2007. The myofibroblast: one function, multiple origins. Am J Pathol 170: 1807-1816.
16. Desmouliere A, Darby IA, Gabbiani G,. 2003. Normal and pathologic soft tissue remodeling: role of the myofibroblast, with special emphasis on liver and kidney fibrosis. Lab Invest 83: 1689-1707.
17. Walker GA, Masters KS, Shah DN, et al. 2004. Valvular myofibroblast activation by transforming growth factor-β: implications for pathological extracellular matrix remodeling in heart valve disease. Circ Res 95: 253-260.
18. Hinz B,. The myofibroblast: paradigm for a mechanically active cell. J Biomech 43: 146-155.
19. Powell DW, Mifflin RC, Valentich JD, et al. 1999. Myofibroblasts. I. Paracrine cells important in health and disease. Am J Physiol 277: C1-C9.
20. Reinhold D, Bank U, Buhling F, et al. 1997. A detailed protocol for the measurement of TGF-beta1 in human blood samples. J Immunol Methods 209: 203-206.
21. Das AM, Griswold DE, Molloy CJ, et al. 2004. Fighting pulmonary fibrosis: new science brings new therapeutic opportunities. Drug Discov Today 1: 361-368.
22. Xu Q, Norman JT, Shrivastav S, et al. 2007. In vitro models of TGF-β-induced fibrosis suitable for high-throughput screening of antifibrotic agents. Am J Physiol Renal Physiol 293: F631-F640.
23. Wynn TA,. 2008. Cellular and molecular mechanisms of fibrosis. J Pathol 214: 199-210.
24. Baricos WH, Cortez SL, Deboisblanc M, et al. 1999. Transforming growth factor-β is a potent inhibitor of extracellular matrix degradation by cultured human mesangial cells. J Am Soc Nephrol 10: 790-795.
25. Izzi L, Attisano L,. 2004. Regulation of the TGF β signalling pathway by ubiquitin-mediated degradation. Oncogene 23: 2071-2078.
26. Leask A, Abraham DJ,. 2004. TGF-β signaling and the fibrotic response. FASEB J 18: 816-827.
27. Kisseleva T, Brenner DA,. 2008. Mechanisms of fibrogenesis. Exp Biol Med (Maywood) 233: 109-122.
28. Kisseleva T, Brenner DA,. 2008. Fibrogenesis of parenchymal organs. Proc Am Thorac Soc 5: 338-342.
29. Peters H, Eisenberg R, Daig U, et al. 2004. Platelet inhibition limits TGF-β overexpression and matrix expansion after induction of anti-thy1 glomerulonephritis. Kidney Int 65: 2238-2248.
30. Giovanini AF, Deliberador TM, Gonzaga CC, et al. 2010. Platelet-rich plasma diminishes calvarial bone repair associated with alterations in collagen matrix composition and elevated CD34+ cell prevalence. Bone 46: 1469-1674.
31. Gronthos S, Stewart K, Graves SE, et al. 1997. Integrin expression and function on human osteoblast-like cells. J Bone Miner Res 12: 1189-1197.
32. Phan SH,. 2002. The myofibroblast in pulmonary fibrosis. Chest 122: 286S-289S.
33. Manetti M, Neumann E, Milia AF, et al. 2007. Severe fibrosis and increased expression of fibrogenic cytokines in the gastric wall of systemic sclerosis patients. Arthritis Rheum 56: 3442-3447.
34. Abraham DJ, Varga J,. 2005. Scleroderma: from cell and molecular mechanisms to disease models. Trends Immunol 26: 587-595.
35. Zhu J, Li Y, Shen W, et al. 2007. Relationships between transforming growth factor-β 1, myostatin, and decorin: implications for skeletal muscle fibrosis. J Biol Chem 282: 25852-25863.
36. Brenmoehl J, Miller SN, Hofmann C, et al. 2009. Transforming growth factor-β 1 induces intestinal myofibroblast differentiation and modulates their migration. World J Gastroenterol 15: 1431-1442.
37. Popova AP, Bozyk PD, Goldsmith AM, et al. 2010. Autocrine production of TGF-β 1 promotes myofibroblastic differentiation of neonatal lung mesenchymal stem cells. Am J Physiol Lung Cell Mol Physiol 298: L735-L743.
38. Simmons JG, Pucilowska JB, Keku TO, et al. 2002. IGF-I and TGF-β 1 have distinct effects on phenotype and proliferation of intestinal fibroblasts. Am J Physiol Gastrointest Liver Physiol 283: G809-G818.
39. Georges PC, Hui JJ, Gombos Z, et al. 2007. Increased stiffness of the rat liver precedes matrix deposition: implications for fibrosis. Am J Physiol Gastrointest Liver Physiol 293: G1147-G1154.
40. Wells RG,. 2008. The role of matrix stiffness in regulating cell behavior. Hepatology 47: 1394-1400.
41. Kissin E, Korn JH,. 2002. Apoptosis and myofibroblasts in the pathogenesis of systemic sclerosis. Curr Rheumatol Rep 4: 129-135.
42. Chauhan H, Abraham A, Phillips JR, et al. 2003. There is more than one kind of myofibroblast: analysis of CD34 expression in benign, in situ, and invasive breast lesions. J Clin Pathol 56: 271-276.
43. Chen XD, Dusevich V, Feng JQ, et al. 2007. Extracellular matrix made by bone marrow cells facilitates expansion of marrow-derived mesenchymal progenitor cells and prevents their differentiation into osteoblasts. J Bone Miner Res 22: 1943-1956.